MustGrow Biologics назначила финансового директора и одобрила выпуск акций для совета директоров

Saskatoon, Saskatchewan--(Newsfile Corp. - September 4, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company and that the board of directors of the Company has authorized and approved the grant of a total of 1,126,954 deferred share units of the Company ("DSUs") to directors (excluding the Company's Chief Excutive Officer and Chief Operating Officer) and Mr. Reinheimer, effective September 3, 2026. This grant of DSUs is made pursuant to the Company's omnibus equity incentive plan. The DSUs will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable. On settlement, each DSU will entitle the holder thereof to receive one common share in the capital of the Company, or a cash payment equivalent thereof at the discretion of the Company. About MustGrow MustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 70.4 million common shares issued and outstanding, and approximately 93.0 million shares on a fully diluted basis. Contact Information Corey Giasson Director & CEO Phone: +1-306-668-2652 [email protected] This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States. Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2026 MustGrow Biologics Corp. All rights reserved. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312925